Atlas Trials

Exploratory Clinical Study of Camrelizumab Combined With Concurrent Chemoradiotherapy as an Organ-preserving Strategy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Clinical trial NCT07622797 · RECRUITING

Trial details

NCT number
NCT07622797
Sponsor
The First Affiliated Hospital of Henan University of Science and Technology
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Late-stage Resectable Esophageal Squamous Carcinoma
Start date
2025-11-21
Primary completion
2028-12-31
Enrollment
164

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.